CeriBell (NASDAQ:CBLL) VP David Foehr Sells 859 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 859 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $23.95, for a total transaction of $20,573.05. Following the transaction, the vice president directly owned 35,899 shares of the company’s stock, valued at $859,781.05. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $23,851.86.

CeriBell Price Performance

Shares of CeriBell stock opened at $23.95 on Wednesday. The stock has a 50 day moving average of $19.77 and a 200 day moving average of $19.27. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33. The firm has a market cap of $919.20 million, a PE ratio of -13.61 and a beta of 0.81. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, research analysts expect that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on CBLL. Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. BTIG Research upped their price objective on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently made changes to their positions in CBLL. California State Teachers Retirement System boosted its stake in shares of CeriBell by 409.5% during the 2nd quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock worth $143,000 after purchasing an additional 5,909 shares during the period. Wellington Management Group LLP raised its position in CeriBell by 5.5% in the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares during the period. Formula Growth Ltd. bought a new stake in CeriBell in the second quarter worth about $603,000. Bank of America Corp DE purchased a new position in shares of CeriBell during the second quarter valued at approximately $4,619,000. Finally, PDT Partners LLC purchased a new position in shares of CeriBell during the second quarter valued at approximately $1,026,000.

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares for about $307,000. Each filing stated that the shares were sold to cover tax-withholding obligations after equity awards vested, and the executives retained substantial remaining holdings. SEC insider transaction filings
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from zero shares on August 10, with a zero-day days-to-cover ratio. Because the figures include a “NaN” change and may reflect incomplete or anomalous reporting, they provide little actionable information about bearish positioning.
• Negative Sentiment: The cluster of sales by multiple senior executives could create a modest overhang for CBLL, particularly with the stock trading close to its 12-month peak. However, the relatively small size of the transactions and their stated tax-related purpose lessen the signal that management is broadly reducing exposure.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.